Multiple criteria decision analysis for HTA across four EU member states: piloting the Advance Value Framework

Angelis, Aris ORCID: 0000-0002-0261-4634, Linch, Mark, Montibeller, Gilberto, Molina Lopez, Maria Teresa, Zawada, Anna, Orzel, Kinga, Arickx, Francis, Espin, Jaime and Kanavos, Panos ORCID: 0000-0001-9518-3089 (2020) Multiple criteria decision analysis for HTA across four EU member states: piloting the Advance Value Framework. Social Science & Medicine, 246. ISSN 0277-9536

	Text (Multiple criteria decision analysis) - Accepted Version Available under License Creative Commons Attribution. Download (2MB)
	Text (1-s2.0-S0277953619305908-main) - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (2MB)

• Author
• Author

Abstract

Multiple Criteria Decision Analysis (MCDA) has emerged as a methodology for Health Technology Assessment (HTA). However, limited empirical evidence is available on its use by decision-makers; where available, it only comes from single-setting exercises, while cross-country comparative studies are unavailable. This study applies the Advance Value Framework (AVF), an MCDA methodology for HTA based on multi-attribute value theory, through a series of case studies with decision-makers in four countries, to explore its feasibility and compare decision-makers' value preferences and results. The AVF was applied in the evaluation of three drugs for metastatic, castrate resistant, prostate cancer (abiraterone, cabazitaxel and enzalutamide) in the post-chemotherapy indication. Decision conferences were organised in four European countries in collaboration with their HTA or health insurance organisations by involving relevant assessors and experts: Sweden (TLV), Andalusia/Spain (AETSA), Poland (AOTMiT) and Belgium (INAMI-RIZIV). Participants' value preferences, including performance scoring and criteria weighting, were elicited through a facilitated decision-analysis modelling approach using the MACBETH technique. Between 6 and 11 criteria were included in each jurisdiction's value model, allocated across four criteria domains; Therapeutic Benefit criteria consistently ranked first in relative importance across all countries. Consistent drug rankings were observed in all settings, with enzalutamide generating the highest overall weighted preference value (WPV) score, followed by abiraterone and cabazitaxel. Dividing drugs' overall WPV scores by their costs produced the lowest “cost per unit of value” for enzalutamide, followed by abiraterone and cabazitaxel. These results come in contrast with the actual country HTA recommendations and pricing decisions. Overall, although some differences in value preferences were observed between countries, drug rankings remained the same. The MCDA methodology employed could act as a decision support tool in HTA, due to the transparency in the construction of value preferences in a collaborative manner.

Item Type:	Article
Official URL:	https://www.sciencedirect.com/journal/social-scien...
Additional Information:	© 2019 The Author(s)
Divisions:	LSE Health Health Policy
Subjects:	R Medicine > RM Therapeutics. Pharmacology R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Date Deposited:	16 Oct 2019 09:57
Last Modified:	09 Nov 2024 01:06
URI:	http://eprints.lse.ac.uk/id/eprint/102122

Actions (login required)

View Item